VIRIDIAN THERAPEUTICS INC. - COMMON STOCK

Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022

03 May 2022 08:00:02 By Nasdaq GlobeNewswire

Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14

06 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital

04 Apr 2022 16:05:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

21 Mar 2022 16:05:00 By Nasdaq GlobeNewswire

Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15

14 Mar 2022 16:05:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates

10 Mar 2022 16:05:01 By Nasdaq GlobeNewswire

Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022

03 Mar 2022 16:16:09 By Nasdaq GlobeNewswire

Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18

14 Feb 2022 08:00:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

31 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

04 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

20 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R Antibody for the Treatment of Thyroid Eye Disease (TED)

15 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Viridian Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

04 Nov 2021 16:05:02 By Nasdaq GlobeNewswire

Viridian Therapeutics to Present at Upcoming Investor Conferences

03 Nov 2021 16:05:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration

14 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association

30 Sep 2021 08:06:29 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Preferred Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

23 Sep 2021 16:01:00 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock and Preferred Stock

21 Sep 2021 00:22:28 By Nasdaq GlobeNewswire

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

20 Sep 2021 16:01:00 By Nasdaq GlobeNewswire